Ear-Seizure Detection (EarSD) Study
Launched by FELICIA CHU · Sep 13, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The Ear-Seizure Detection (EarSD) Study is a research project that aims to test a new wearable device designed to detect and predict seizures in people with epilepsy. This study will compare the device's accuracy to traditional methods of tracking seizures, which include video and brain wave recordings done in a hospital setting. Participants will wear this device while they are monitored in the Epilepsy Monitoring Unit at UMass Memorial Hospital.
To join this study, participants need to be at least 18 years old and currently undergoing long-term video-EEG monitoring for epilepsy. They should be willing to wear the device and be able to give their consent to participate. People who use other ear devices, have skin irritation where the device will be placed, or have certain medical conditions, such as being pregnant or having cognitive impairments, won't be eligible. Those who participate can expect to wear the device while their seizures are being observed, helping researchers learn how well this new technology works in real-time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years.
- • 2. Patients admitted to UMass Memorial Epilepsy Monitoring Unit (EMU) for long term video-EEG monitoring as part of standard care of both focal and generalized epilepsy.
- • 3. Willing to wear the wearable device.
- • 4. Ability to provide informed consent
- Exclusion Criteria:
- • 1. Subjects wearing other ear devices such as hearing aids.
- • 2. Inability or unwillingness to provide informed consent.
- • 3. Irritation of the skin where the device is to be placed.
- • 4. Patients with intracranial electrodes placement.
- • 5. Prisoners
- • 6. Cognitive impaired individuals
- • 7. Pregnant Women
- • 8. Children (Age 0-17)
About Felicia Chu
Felicia Chu is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the pharmaceutical and biotechnology sectors, she focuses on innovative therapies and cutting-edge treatments across various therapeutic areas. Felicia emphasizes rigorous study design, regulatory compliance, and ethical standards, ensuring that all clinical trials are conducted with the utmost integrity and scientific rigor. Her leadership fosters collaboration among multidisciplinary teams, driving the successful execution of trials that contribute to the advancement of healthcare and the well-being of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Worcester, Massachusetts, United States
Worcester, Massachusetts, United States
Patients applied
Trial Officials
Felicia Chu, MD
Principal Investigator
UMass Neurology Department
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported